tegafur has been researched along with Thrombocytopenia in 39 studies
Thrombocytopenia: A subnormal level of BLOOD PLATELETS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA)." | 9.16 | Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. ( Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2012) |
| "A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989." | 9.07 | A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994) |
| "Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)." | 7.67 | Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984) |
| "Twenty-nine patients with metastatic breast cancer were treated with a combination chemotherapy consisting of Epirubicin 50 mg/m2 IV on day 1, Cyclophosphamide 500 mg/m2 IV on day 1 and Ftorafur 800 mg/day PO every day (ECF therapy)." | 7.67 | [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer]. ( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Ogawa, M; Shinagawa, K; Tabata, M, 1988) |
| "We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA)." | 5.16 | Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. ( Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2012) |
| "A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989." | 5.07 | A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994) |
| "Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)." | 3.67 | Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984) |
| "Twenty-nine patients with metastatic breast cancer were treated with a combination chemotherapy consisting of Epirubicin 50 mg/m2 IV on day 1, Cyclophosphamide 500 mg/m2 IV on day 1 and Ftorafur 800 mg/day PO every day (ECF therapy)." | 3.67 | [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer]. ( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Ogawa, M; Shinagawa, K; Tabata, M, 1988) |
| "Twenty-five adult patients with adenocarcinoma of unknown primary origin were treated with oral tegafur followed by the combination of cyclophosphamide/adriamycin/cis-diamminedichloroplatinum(II) (CAP) if they failed to respond to tegafur." | 3.66 | Sequential chemotherapy for adenocarcinoma of unknown primary. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983) |
| "Previous studies have shown sex-related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown." | 2.90 | Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. ( Amagai, K; Chin, K; Fujii, H; Fuse, N; Gotoh, M; Hironaka, S; Hyodo, I; Imamura, H; Koizumi, W; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2019) |
| "Paclitaxel (160 mg/m²) was administered by infusion for 3 h on the first day." | 2.76 | A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer. ( Goto, H; Haruta, J; Ina, K; Iwase, H; Kumada, T; Shimada, M; Shinoda, M; Sugihara, M; Tsuzuki, T, 2011) |
| "Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks." | 2.76 | Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011) |
| " Pharmacokinetic analyses were performed following a single dose of S-1 on D-5 and D1 of the first cycle." | 2.75 | Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. ( Bae, KS; Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ; Yoo, C, 2010) |
| "Optimal chemotherapy for advanced biliary tract cancer (BTC) is yet to be defined." | 2.73 | A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. ( Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, HG; Kim, JH; Kim, SW; Kim, TY; Kim, YJ; Lee, KW; Lee, SH; Oh, DY; Oh, SY; Yoon, YB, 2008) |
| "The incidence and mortality of pancreatic cancer has increased very rapidly in Japan." | 2.72 | [Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer]. ( Ishihara, T; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T, 2006) |
| "Chemoradiotherapy combined with 5-fluorouracil and cisplatin have been effective for the treatment of advanced esophageal cancer, but superior treatments are needed." | 2.72 | [Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer]. ( Iwase, H, 2006) |
| ") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers." | 2.71 | Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. ( Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005) |
| "Oral tegafur and I." | 2.65 | A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. ( Bedikian, AY; Bodey, GP; Karlin, D; Korinek, J; Stroehlein, J, 1983) |
| "Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC." | 1.46 | Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017) |
| " The baseline characteristics, progressive-free survival, overall survival time and adverse events were retrospectively analyzed." | 1.40 | [Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses]. ( Guo, Z; Hong, L; Li, B; Liu, C; Si, T; Yu, H, 2014) |
| " The types and incidence rate of adverse events related to chemotherapy and the results of follow up of the patients were analyzed." | 1.38 | [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer]. ( Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y, 2012) |
| "Grade 3 leukocytopenia was observed in 1 patient (8." | 1.35 | Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. ( Dono, K; Kobayashi, S; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Noda, T; Takeda, Y; Umeshita, K; Wada, H, 2008) |
| "As a measure to ensure safe use of TS-1 during the early marketing period, a drug use investigation was conducted on an all-case basis." | 1.33 | [Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--]. ( Ito, K, 2006) |
| "We report a case of advanced squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to oral chemotherapy with TS-1." | 1.32 | [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1]. ( Mishima, K; Nakamura, H; Obara, S; Yamamoto, K; Yoshimura, Y, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (15.38) | 18.7374 |
| 1990's | 3 (7.69) | 18.2507 |
| 2000's | 14 (35.90) | 29.6817 |
| 2010's | 15 (38.46) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Kasai, T | 1 |
| Mori, K | 1 |
| Kishi, K | 1 |
| Kaburagi, T | 1 |
| Hosomi, Y | 1 |
| Imai, H | 2 |
| Yamada, Y | 2 |
| Yomota, M | 1 |
| Moriguchi, S | 1 |
| Seike, M | 1 |
| Minato, K | 1 |
| Gemma, A | 1 |
| Hamada, C | 1 |
| Okusaka, T | 2 |
| Ikari, T | 1 |
| Isayama, H | 1 |
| Furuse, J | 2 |
| Ishii, H | 1 |
| Nakai, Y | 1 |
| Imai, S | 1 |
| Okamura, S | 1 |
| Koizumi, W | 1 |
| Nishikawa, K | 1 |
| Gotoh, M | 1 |
| Fuse, N | 1 |
| Sugimoto, N | 1 |
| Nishina, T | 1 |
| Amagai, K | 1 |
| Chin, K | 1 |
| Niwa, Y | 1 |
| Tsuji, A | 1 |
| Imamura, H | 3 |
| Tsuda, M | 1 |
| Yasui, H | 2 |
| Fujii, H | 1 |
| Yamaguchi, K | 2 |
| Hironaka, S | 1 |
| Shimada, K | 1 |
| Hyodo, I | 1 |
| Iwase, H | 3 |
| Shimada, M | 2 |
| Tsuzuki, T | 2 |
| Hirashima, N | 1 |
| Okeya, M | 1 |
| Hibino, Y | 1 |
| Ryuge, N | 1 |
| Yokoi, M | 1 |
| Kida, Y | 1 |
| Kuno, T | 1 |
| Tanaka, Y | 1 |
| Kato, B | 1 |
| Esaki, M | 1 |
| Urata, N | 1 |
| Kato, E | 1 |
| Komazaki, Y | 1 |
| Sakashita, H | 1 |
| Furuiye, M | 1 |
| Fujie, T | 1 |
| Tamaoka, M | 1 |
| Sumi, Y | 1 |
| Miyazaki, Y | 1 |
| Kojima, K | 1 |
| Jin, Y | 1 |
| Inase, N | 1 |
| Sato, D | 1 |
| Kogashiwa, Y | 1 |
| Tsukahara, K | 1 |
| Yamauchi, K | 1 |
| Kohno, N | 1 |
| Wang, M | 1 |
| Wu, M | 1 |
| Wang, W | 1 |
| Wang, Q | 1 |
| Wang, Y | 1 |
| Hong, L | 1 |
| Guo, Z | 1 |
| Yu, H | 1 |
| Li, B | 1 |
| Si, T | 1 |
| Liu, C | 1 |
| Park, I | 1 |
| Lee, JL | 3 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Kim, TW | 3 |
| Sym, SJ | 1 |
| Lee, SS | 3 |
| Jang, G | 1 |
| Yoo, C | 1 |
| Bae, KS | 1 |
| Kang, YK | 1 |
| Kaira, K | 1 |
| Sunaga, N | 1 |
| Yanagitani, N | 1 |
| Utsugi, M | 1 |
| Iwasaki, Y | 1 |
| Shimizu, K | 1 |
| Iijima, H | 1 |
| Tsurumaki, H | 1 |
| Tomizawa, Y | 1 |
| Hisada, T | 1 |
| Ishizuka, T | 1 |
| Saito, R | 1 |
| Mori, M | 1 |
| Hong, YS | 1 |
| Park, JH | 1 |
| Kim, JH | 2 |
| Yoon, SN | 1 |
| Lim, SB | 1 |
| Yu, CS | 1 |
| Kim, MJ | 1 |
| Jang, SJ | 1 |
| Lee, JS | 1 |
| Kim, JC | 1 |
| Ina, K | 1 |
| Sugihara, M | 1 |
| Haruta, J | 1 |
| Shinoda, M | 1 |
| Kumada, T | 1 |
| Goto, H | 1 |
| Ueno, H | 1 |
| Yamao, K | 1 |
| Funakoshi, A | 1 |
| Boku, N | 1 |
| Ohkawa, S | 1 |
| Yokosuka, O | 1 |
| Tanaka, K | 1 |
| Moriyasu, F | 1 |
| Nakamori, S | 1 |
| Sato, T | 1 |
| Ichinose, Y | 2 |
| Seto, T | 1 |
| Sasaki, T | 1 |
| Yamanaka, T | 1 |
| Okamoto, I | 1 |
| Takeda, K | 1 |
| Tanaka, M | 1 |
| Katakami, N | 1 |
| Sawa, T | 1 |
| Kudoh, S | 2 |
| Saka, H | 1 |
| Nishimura, Y | 1 |
| Nakagawa, K | 1 |
| Fukuoka, M | 1 |
| Kang, MJ | 1 |
| Ahn, S | 1 |
| Park, DH | 1 |
| Seo, DW | 1 |
| Lee, SK | 1 |
| Kim, MH | 1 |
| Zhou, Y | 1 |
| Huang, J | 1 |
| Yang, L | 1 |
| Chi, Y | 1 |
| Qu, T | 1 |
| Lü, X | 1 |
| Wang, JW | 1 |
| Chen, JS | 1 |
| Yang, TS | 1 |
| Lin, YC | 1 |
| Jan, YY | 1 |
| Hino, S | 1 |
| Shintani, S | 1 |
| Nonaka, T | 1 |
| Hara, S | 1 |
| Hamakawa, H | 1 |
| Morita, S | 1 |
| Ohashi, Y | 1 |
| Hirakawa, K | 1 |
| Nakata, B | 1 |
| Saji, S | 1 |
| Sakamoto, J | 1 |
| Yamamoto, K | 1 |
| Obara, S | 1 |
| Mishima, K | 1 |
| Nakamura, H | 1 |
| Yoshimura, Y | 1 |
| Watanabe, O | 1 |
| Shimizu, T | 1 |
| Kinoshita, J | 1 |
| Okabe, T | 1 |
| Ogawa, K | 1 |
| Haga, S | 1 |
| Nio, Y | 1 |
| Hashimoto, K | 1 |
| Yano, S | 1 |
| Itakura, M | 1 |
| Koike, M | 1 |
| Endo, S | 1 |
| Tsuji, M | 1 |
| Higami, T | 1 |
| Maruyama, R | 1 |
| Ito, K | 1 |
| Fujii, M | 1 |
| Nakamura, K | 1 |
| Yamaguchi, T | 1 |
| Sudo, K | 1 |
| Ishihara, T | 1 |
| Saisho, H | 1 |
| Maruoka, Y | 1 |
| Ando, T | 1 |
| Ogiuchi, Y | 1 |
| Ogiuchi, H | 1 |
| Kim, YJ | 1 |
| Im, SA | 1 |
| Kim, HG | 1 |
| Oh, SY | 1 |
| Lee, KW | 1 |
| Choi, IS | 1 |
| Oh, DY | 1 |
| Lee, SH | 1 |
| Kim, DW | 1 |
| Kim, TY | 1 |
| Kim, SW | 1 |
| Heo, DS | 1 |
| Yoon, YB | 1 |
| Bang, YJ | 1 |
| Takiuchi, H | 1 |
| Goto, M | 1 |
| Furukawa, H | 1 |
| Imano, M | 1 |
| Imamoto, H | 1 |
| Kimura, Y | 1 |
| Ishida, H | 1 |
| Fujitani, K | 1 |
| Narahara, H | 1 |
| Shimokawa, T | 1 |
| Nakamura, M | 1 |
| Nagano, H | 1 |
| Marubashi, S | 1 |
| Miyamoto, A | 1 |
| Takeda, Y | 1 |
| Kobayashi, S | 1 |
| Wada, H | 1 |
| Noda, T | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Monden, M | 1 |
| Salvati, F | 1 |
| Cruciani, AR | 1 |
| De Marinis, A | 1 |
| Nunziati, F | 1 |
| Portalone, L | 1 |
| Bedikian, AY | 2 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Bodey, GP | 2 |
| Valdivieso, M | 1 |
| Burgess, MA | 1 |
| Reyes, JM | 1 |
| Okazaki, N | 1 |
| Yoshino, M | 1 |
| Yoshida, T | 1 |
| Tashiro, H | 1 |
| Nomura, Y | 1 |
| Ohsaki, A | 1 |
| Ono, T | 1 |
| Komatsu, M | 1 |
| Hoshino, T | 1 |
| Ishii, T | 1 |
| Fujii, K | 1 |
| Ohshima, S | 1 |
| Mikami, K | 1 |
| Masamune, O | 1 |
| Fukuda, T | 1 |
| Yano, T | 1 |
| Yoshimori, K | 1 |
| Morikawa, T | 1 |
| Kuba, M | 1 |
| Niitani, H | 1 |
| Diggs, CH | 1 |
| Wiernik, PH | 1 |
| Smyth, AC | 1 |
| Shinagawa, K | 1 |
| Ogawa, M | 1 |
| Horikoshi, N | 1 |
| Inoue, K | 1 |
| Mukaiyama, T | 1 |
| Fukutani, H | 1 |
| Tabata, M | 1 |
| Hirano, A | 1 |
| Mizunuma, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| PD-1 Antibody Plus Gemcitabine and Oxaliplatin (GEMOX) as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma Patients With Positively Metastatic Lymph Nodes : a Single Arm, Phase II Trial[NCT05430698] | Phase 2 | 62 participants (Anticipated) | Interventional | 2023-01-31 | Recruiting | ||
| Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer[NCT01375972] | Phase 2 | 92 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for tegafur and Thrombocytopenia
| Article | Year |
|---|---|
[Combination therapy with S-1 and CDDP for head and neck cancer].
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinom | 2006 |
23 trials available for tegafur and Thrombocytopenia
| Article | Year |
|---|---|
A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2020 |
Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Respons | 2019 |
Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Feasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemothe | 2013 |
Phase I study of nedaplatin prior to S-1 in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Sch | 2013 |
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relat | 2010 |
Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2010 |
Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2011 |
A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Surviva | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ad | 2011 |
S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2011 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia | 2012 |
A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neo | 2003 |
Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[Clinical usefulness of UFT and cyclophosphamide as salvage chemotherapy for patients with metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2005 |
[Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2006 |
[Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2006 |
A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2008 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |
A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Injections, | 1983 |
A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Meth | 1994 |
UFT plus cisplatin in advanced non-small-cell lung cancer: interim analysis of 67 patients.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cispla | 1997 |
15 other studies available for tegafur and Thrombocytopenia
| Article | Year |
|---|---|
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2017 |
Docetexal plus S-1 versus oxaliplatin plus S-1 for first-line treatment of patients with advanced gastric cancer: a retrospective study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Huma | 2014 |
[Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Hum | 2014 |
[A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
[A case of advanced maxillary carcinoma with cervical lymph node metastases showing a complete response to the combination therapy of CDDP, TS-1 and radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2004 |
[An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administrat | 2004 |
[Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--].
Topics: Antimetabolites, Antineoplastic; Capsules; Drug Administration Schedule; Drug Combinations; Drug Mon | 2006 |
[Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2008 |
Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Br | 1984 |
Sequential chemotherapy for adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1983 |
Phase II study of orally and rectally administered Tegafur in liver metastases from gastric carcinoma.
Topics: Administration, Oral; Adult; Aged; Drug Evaluation; Female; Fluorouracil; Humans; Liver Neoplasms; M | 1984 |
[A case of advanced gastric cancer with multiple liver metastasis successfully treated with combination chemotherapy using UFT, CDDP and etoposide].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 1996 |
Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
Topics: Adenocarcinoma; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Leuko | 1977 |
[Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 1988 |